Abbott Laboratories 10-Q Summary: Period Ended June 30, 1998
Business Context and Reporting Period
This is an unaudited quarterly report (Form 10-Q) for Abbott Laboratories, an Illinois corporation, for the period ended June 30, 1998. The company operates primarily in pharmaceutical, nutritional, hospital, and laboratory products. As of July 31, 1998, the company had approximately 1.54 billion common shares outstanding. A two-for-one stock split was executed in May 1998, and all per-share data in this report has been adjusted to reflect this split.
Key Financial Metrics
| Metric | Six Months Ended June 30, 1998 | Six Months Ended June 30, 1997 |
|---|---|---|
| Net Sales | $6,111.7 million | $5,900.2 million |
| Net Earnings | $1,175.2 million | $1,056.4 million |
| Diluted EPS | $0.76 | $0.67 |
| Gross Profit Margin | 57.8% | 56.9% |
| Operating Cash Flow | $1,697.6 million | $1,363.9 million |
| Cash and Equivalents (End of Period) | $251.8 million | $126.5 million |
| Total Debt (Short-term + Long-term) | $2,716.7 million | $2,719.3 million (Dec 31, 1997) |
Note: Debt figures for 1997 are based on the December 31, 1997 balance sheet as the comparative six-month balance sheet is not provided in the text.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 3.6% year-over-year for the six-month period. Excluding the negative impact of a stronger U.S. dollar, sales growth was 6.9%.
- Profitability: Net earnings rose 11.2% to $1.175 billion. Diluted earnings per share increased 13.4%.
- Acquisitions: The company acquired International Murex Technologies Corporation for approximately $234 million in cash in April 1998. This acquisition was funded through commercial paper borrowings.
- Share Repurchases: The company purchased and retired 11.4 million shares of common stock during the first six months of 1998 at a cost of $426 million.
- Foreign Exchange: A stronger U.S. dollar negatively impacted sales and gross profit margins. Net foreign exchange losses were $15.0 million for the six-month period, compared to a gain of $6.8 million in the prior year.
Outlook, Risks, and Unusual Items
- Manufacturing Disruption: On July 27, 1998, the company announced manufacturing difficulties with the capsule formulation of its protease inhibitor, Norvir. This resulted in supply shortages. The company plans to supply the liquid formulation as an alternative. Sales of Norvir for the first six months were $125.5 million; the future financial impact is currently unquantifiable.
- Litigation Settlements: The company entered into an agreement to settle a federal class action lawsuit regarding pharmaceutical pricing for $57 million (pending court approval). Additionally, 12 consumer lawsuits were settled for a total of $1.65 million. Management believes these matters will not have a material adverse effect on financial position.
- Legislative Risks: The company faces ongoing regulatory and legislative risks regarding healthcare pricing and delivery, which could reduce prices or limit price increases.
- Year 2000 (Y2K): The company is actively remediating internal systems, embedded systems, and supplier dependencies. Remediation costs are expensed as incurred and are not expected to be material to cash flow or operations.
- Accounting Standards: The company is assessing the impact of FASB Statement No. 133 regarding derivative instruments, effective for fiscal years beginning after June 15, 1999.
Investor Verification Checklist
- Verify the final court approval status of the $57 million antitrust class action settlement.
- Monitor the resolution of the Norvir capsule manufacturing issues and the resulting impact on future sales volumes.
- Review the company's progress on Y2K remediation for critical systems and supplier compliance.
- Assess the impact of the stronger U.S. dollar on future international sales growth.
- Confirm the status of the $200 million debt issuance and the utilization of the remaining $200 million under the registration statement.